Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Devax has completed patient enrollment in the Diverge clinical trial evaluating its novel Axxess Bifurcation stent system, a proprietary self-expanding Nitinol stent specifically engineered for the treatment of coronary and vascular bifurcation lesions.
Subscribe to our email newsletter
The Diverge trial, a prospective, multi-center trial which enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions.
Paul Buckman, CEO of Devax, said: “The Diverge data will help guide our development and registration strategy to deliver to the market the first drug-eluting stent specifically designed for bifurcation lesions.”